Abstract
Studies for developing diagnostics and treatments for infectious diseases usually require observing the onset of infection during the study period. However, when the infection base rate incidence is low, the cohort size required to measure an effect becomes large, and recruitment becomes costly and prolonged. We describe an approach for reducing recruiting time and resources in a COVID-19 study by targeting recruitment to high-risk individuals. Our approach is based on direct and longitudinal connection with research participants and computes individual risk scores from individually permissioned data about socioeconomic and behavioural data, in combination with predicted local prevalence data. When we used these scores to recruit a balanced cohort of participants for a COVID-19 detection study, we obtained a 4–7-fold greater COVID-19 infection incidence compared with similar real-world study cohorts.
Competing Interest Statement
E.R., A.M., L.L., S.E, E.C, and L.F. are employees of Evidation Health, Inc., developers of the Evidation health and research platform.
Funding Statement
This project was funded in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract number 75A50120C00091. Additional support was provided by an appointment to the Biomedical Advanced Research and Development Authority (BARDA) Research Participation Program administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy (DOE) and the U.S. Department of Health and Human Services (HHS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The WCG IRB (Puyallup, Washington, USA) gave ethical approval for this study. Study number 1292395, IRB Tracking Number: 20202887
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Co-first authors.
Data Availability
The datasets analysed in this study are not publicly available but can be shared for scientific collaboration by contacting the corresponding author.
